The efficacy and safety of regorafenib taking 5 days and stop 2 days for the third-line treatment in mRCR patients
收藏NIAID Data Ecosystem2026-03-11 收录
官方服务：
资源简介：
Interventions: experimental group:Regorafenib, taking 5 days and stop 2 days;control group:Regorafenib, once a day Primary outcome(s): Progression-Free Survival Study Design: Parallel
创建时间：
2020-05-15
